BioInformant

Your Global Leader in Stem Cell Market Research

Home » hematopoietic stem cells » Page 3

We Analyzed a Decade of Historical Information on Cord Blood & Cord Tissue Markets (This Is What We Learned)

By

The cord blood banking market is complex. There are regions experiencing growth and regions experiencing decline. There are extremely successful cord blood banks, and banks that are going out of business or being acquired by the competition.

In addition, there are unique opportunities occurring within the cord blood space that are based on emerging technologies, such as ex vivo expansion of cord blood.

The cord tissue market is also complex, although for different reasons. Today, half of all cord blood banks worldwide offer this service and the number is accelerating. Interestingly, the mesenchymal stem cells (MSCs) contained in cord tissue may have growing opportunities relative to the hematopoietic stem cells (HSCs) contained in cord blood, because MSCs just surpassed HSCs in the scientific literature for the first time in history.

For this reason, BioInformant is offering industry-leading market intelligence for both cord blood and cord tissue markets for the next 14 days only. 

Act by Feb 29, 2016, and you can get two reports for the price of one, a savings of $3,795.

CORD BLOOD + CORD TISSUE PACKAGE:

This is an exclusive offer available only to BioInformant readers, so enter the coupon code “CordBloodCordTissue” during checkout (for either product) and you will automatically receive the other report for free. 

To compete within the global cord blood banking market, you need to be informed about both cord blood and cord tissue markets. This is your opportunity to get a strategic edge.

[Read more…]

Is It the Era for Mesenchymal Stem Cells (MSCs)?

By

Wow! For the first time in history, the research of mesenchymal stem cells surpassed hematopoietic stem cell research within the scientific literature in 2015.

This is major news for the stem cell community, because it represents a shift in stem cell research activity.

Mesenchymal stem cells, of the five types analyzed, were the only type to also experience an increase in frequency of publication from 2014 to 2015 as well. Conversely, all four other types experienced decreases in publication during the aforementioned period.

Check out the metrics here: Mesenchymal Stem Cells Surpass Hematopoietic Stem Cells in the Scientific Literature for the 1st Time in History [Read more…]

Cord Blood Banks – Anticipate and Serve the Needs of Your Clients, Or Your Competitors Will

By

One of BioInformant’s market reports is the “Complete 2015-16 Cord Blood Banking Industry Report.” Popular among cord blood banks, biobanks, cell therapy companies, and industry investors, the report is filled with 204 pages of critical industry metrics.

Recently, a business partner asked me what makes this market report unique.

It is an excellent question, because there are massive differences between this report and other variations of market and industry reports for the cord blood industry.

To learn more about the importance of choosing a qualified provider of cord blood market information, read the article, “Why I Respectfully Disagree with Other Market Intelligence Reports about Cord Blood Banking.” [Read more…]

Why I Respectfully Disagree with Other Market Intelligence Reports about Cord Blood Banking

By

Recently, I’ve seen posts on LinkedIn and the web for a cord blood market report titled “Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 – 2020.”

I rarely reflect on products by other companies, but this report is disturbing in that it is painfully inaccurate.

As global business expert Joe Polish likes to say, “The most expensive information is bad information,” and this is a case of that situation.

In the Executive Summary, a highlight of the main findings for this report, Allied Market Research states that the “Cord blood market is expected to grow at 33.5% CAGR from 2012-2020.”
[Read more…]

Stem Cell Therapeutic & Research Act and a Critical Appraisal of Cord Blood Quality

By

Opinion Article: This is an article written by Ivan N. Rich of HemoGenix, Inc., Colorado Springs, CO, USA. It is an opinion piece that reflects views and positions of the author. It does not reflect the views of BioInformant Worldwide, LLC.

As a stem cell and cord blood industry blog, it is our role to spread discussion and allow a voice to varying opinions, perspectives, and areas of scientific expertise. If you have a reaction to this article, ask yourself, why am I reacting? How do I perceive current techniques for cord blood testing and assessment? If you have thoughts, they are encouraged in the comments section below.

November 24, 2015; HemoGenix, Inc. – The passage by voice vote of H.R. 2820, otherwise known as The Stem Cell Therapeutic and Research Reauthorization Act of 2015 through the U.S. House of Representatives [1] has been lauded by many in the cord blood community, including the Cord Blood Association (CBA) that promoted the bill. There is a good chance the Bill will become law, because health issues usually have bipartisan support. Although patients requiring a cord blood stem cell transplant have been helped by previous Bills, they have nevertheless not benefited from the principle purpose of this Bill, namely to provide high-quality cord blood stem cells for transplantation. [Read more…]

BioInformant's World-Class Clients